CN103209705A - 预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法 - Google Patents

预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法 Download PDF

Info

Publication number
CN103209705A
CN103209705A CN2011800403882A CN201180040388A CN103209705A CN 103209705 A CN103209705 A CN 103209705A CN 2011800403882 A CN2011800403882 A CN 2011800403882A CN 201180040388 A CN201180040388 A CN 201180040388A CN 103209705 A CN103209705 A CN 103209705A
Authority
CN
China
Prior art keywords
hiv
antigen
antibody
active
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800403882A
Other languages
English (en)
Chinese (zh)
Inventor
奥列格·伊里奇·爱泼斯坦
谢尔盖·亚历山德罗维奇·塔拉索夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45559675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103209705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN103209705A publication Critical patent/CN103209705A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN2011800403882A 2010-08-06 2011-07-15 预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法 Pending CN103209705A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010133045/15A RU2535033C2 (ru) 2010-08-06 2010-08-06 Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2010133045 2010-08-06
PCT/RU2011/000523 WO2012018284A1 (ru) 2010-08-06 2011-07-15 Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида

Publications (1)

Publication Number Publication Date
CN103209705A true CN103209705A (zh) 2013-07-17

Family

ID=45559675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800403882A Pending CN103209705A (zh) 2010-08-06 2011-07-15 预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法

Country Status (14)

Country Link
US (1) US20130224219A1 (https=)
EP (1) EP2601967A4 (https=)
JP (1) JP2013538195A (https=)
CN (1) CN103209705A (https=)
AU (1) AU2011286486B9 (https=)
CA (1) CA2807540A1 (https=)
DE (1) DE112011102649T5 (https=)
EA (1) EA030411B1 (https=)
ES (1) ES2555557R1 (https=)
GB (1) GB2498276B (https=)
NZ (1) NZ606992A (https=)
RU (1) RU2535033C2 (https=)
UA (1) UA112747C2 (https=)
WO (1) WO2012018284A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA029436B1 (ru) 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения рассеянного склероза и инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способы лечения указанных заболеваний
FR2962656A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
KR101759687B1 (ko) * 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1149822A (zh) * 1994-03-31 1997-05-14 生物医学康姆公司 有治疗作用的生长因子顺势疗法稀释物及其使用方法
CN1303394A (zh) * 1998-06-20 2001-07-11 美国联合生物医学公司 用于预防和治疗hiv感染和免疫疾病的肽组合物
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
RU2195317C1 (ru) * 2001-04-18 2002-12-27 Эпштейн Олег Ильич Способ коррекции патологических иммунных реакций и лекарственное средство
RU2205025C1 (ru) * 2001-12-26 2003-05-27 Гольдберг Евгений Данилович Способ коррекции иммунного ответа и лекарственное средство

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
AU2006281981A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Chimeric antibodies with new world primate regions
EP1987058B1 (en) * 2006-02-10 2010-05-12 ZymoGenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
KR20140012021A (ko) * 2010-08-06 2014-01-29 올레그 일리치 엡쉬테인 감염성 질환의 치료 및 예방을 위한 제약학적 복합 조성물 및 방법들

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1149822A (zh) * 1994-03-31 1997-05-14 生物医学康姆公司 有治疗作用的生长因子顺势疗法稀释物及其使用方法
CN1303394A (zh) * 1998-06-20 2001-07-11 美国联合生物医学公司 用于预防和治疗hiv感染和免疫疾病的肽组合物
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
RU2195317C1 (ru) * 2001-04-18 2002-12-27 Эпштейн Олег Ильич Способ коррекции патологических иммунных реакций и лекарственное средство
RU2205025C1 (ru) * 2001-12-26 2003-05-27 Гольдберг Евгений Данилович Способ коррекции иммунного ответа и лекарственное средство

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
（美）邓恩（DUNNE，L.J.）: "《营养与健康圣典：第五版》", 31 January 2004 *
KUNAL SAHA等: "Isolation of primary HIV-1 that target CD8+ T Lymphocytes using CD8 as a receptor", 《NATURE MEDICINE》 *
李黎等: "细胞因子疫苗的研究进展", 《中国生物制品学杂志》 *
陈武山等: "《新编性病防治手册》", 31 December 2004 *

Also Published As

Publication number Publication date
EP2601967A1 (en) 2013-06-12
GB2498276B (en) 2018-05-23
AU2011286486B9 (en) 2017-02-23
CA2807540A1 (en) 2012-02-09
DE112011102649T5 (de) 2013-06-20
EA201300136A1 (ru) 2013-09-30
ES2555557R1 (es) 2016-02-05
JP2013538195A (ja) 2013-10-10
US20130224219A1 (en) 2013-08-29
AU2011286486A1 (en) 2013-03-28
NZ606992A (en) 2016-03-31
AU2011286486B2 (en) 2017-02-02
GB2498276A (en) 2013-07-10
RU2010133045A (ru) 2012-02-20
GB201303983D0 (en) 2013-04-17
EA030411B1 (ru) 2018-08-31
AU2011286486A2 (en) 2013-05-02
RU2535033C2 (ru) 2014-12-10
EP2601967A4 (en) 2014-05-07
UA112747C2 (uk) 2016-10-25
WO2012018284A1 (ru) 2012-02-09
ES2555557A2 (es) 2016-01-04

Similar Documents

Publication Publication Date Title
CN103209705A (zh) 预防hiv感染以及对由hiv引起的疾病和hiv相关疾病、包括aids进行预防和治疗的药剂和方法
AU2011287292B2 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2535034C2 (ru) Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2577299C2 (ru) Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
CN103154028A (zh) 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
CN103179987A (zh) 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物
US20120263725A1 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
RU2517085C2 (ru) Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2505312C2 (ru) Комплексное лекарственное средство для лечения гриппа различных типов
RU2500422C2 (ru) Комплексное лекарственное средство для лечения вирусных инфекций и способ лечения вирусных инфекций
RU2579262C1 (ru) Лекарственное средство для лечения инфекционных заболеваний
WO2002032452A1 (en) Composition for aids and method producing it
RU2441023C1 (ru) Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2595807C2 (ru) Лекарственное средство для лечения инфекционных заболеваний
RU2542414C2 (ru) Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
CA2807529A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2012017327A2 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717